CHRS 250117 3.00C (CHRS250117C3000) Stock Options, News & Quotes

US OptionsDetailed Quotes

CHRS250117C3000

Watchlist

0.05
0.000.00%

15min DelayTrading Jan 17 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

Coherus Biosciences Presents Final Phase 2 Clinical Casdozokitug Data
TipRanksJan 22 07:10 ET
Coherus Biosciences Announces UDENYCA Divestiture and Revenue Outlook
TipRanksJan 13 16:52 ET
Express News | Coherus BioSciences Inc - FY 2024 Preliminary Net Revenues Expected to Be $255M-$260M
ReutersJan 13 16:27 ET
Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswireJan 8 08:00 ET
Coherus To Present Randomized Phase 2 Study Evaluating The Combination Of Casdozokitug, Toripalimab And Bevacizumab In Patients With Liver Cancer
BenzingaDec 18, 2024 08:45 ET
Biosimilars Market Industry Trends and Global Forecasts to 2035, Featuring Amgen, BIOCAD, Biocon, Celltrion, Coherus BioSciences, Eli Lilly, Fresenius Kabi, Pfizer, Sandoz and Teva Pharmaceuticals - ResearchAndMarkets.com
BusinesswireDec 10, 2024 09:48 ET

Comments

Jaguar8

6 hours ago

NEWS

$Coherus BioSciences (CHRS.US)$
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
Wednesday, 22nd January at 7:00 am
– Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate –
– Antitumor activity was observed across both viral and non-viral etiologies –
– Data support continued...

Trytosaveabit

Dec 18, 2024 07:49

New form 4!

$Coherus BioSciences (CHRS.US)$

Zontex

Dec 16, 2024 09:13

$WISeKey (WKEY.US)$ 🙏🏾

Quantum Computing Rebounds: Can the rise continue?

Jaguar8

Dec 3, 2024 16:27

🟢Watchlist Wednesday, December 4. NFA. Check on my previous watchlist. Those without ✅ means they can have delayed market reaction.

Note: The presence of 30 stock picks reflects the reality that not all stocks respond to their press releases immediately. For instance, today’s market activity saw certain high-performing stocks overshadow promising PRs, suggesting that it may take a day, several days, or even a week for the market to fully digest and react. I encourage you to save the watchlist I p...

71698595

Dec 3, 2024 09:18

$Coherus BioSciences (CHRS.US)$ sucks, not looking good anymore